Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

The trial showed that the double-headed antibody – which targets CD3 on white blood cells and CD20 on tumour ... from the likes of Protheragen and IGM Biosciences in preclinical development.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

2024 — Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called ... Changes in Blood Cell Production Over the ...